Oppenheimer & CO Inc Allogene Therapeutics, Inc. Transaction History

Oppenheimer & CO Inc

$6.42 Billion
Q3 2024

A detailed history of Oppenheimer & CO Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 10,500 shares of ALLO stock, worth $23,835. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,500

Previous 10,500 -0.0%

Holding current value

$23,835

Previous $24,000 20.83%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$2.92 - $5.63 $5,548 - $10,697	-1,900 Reduced 15.32%	10,500 $46,000
Q2 2023 Aug 02, 2023	BUY	$4.53 - $6.74 $56,172 - $83,576	12,400 New	12,400 $61,000
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $53,664 - $89,856	-5,200 Reduced 31.42%	11,350 $123,000
Q2 2022 Aug 08, 2022	BUY	$6.78 - $12.28 $10,170 - $18,420	1,500 Added 9.97%	16,550 $189,000
Q1 2022 May 12, 2022	BUY	$7.65 - $15.29 $22,950 - $45,870	3,000 Added 24.9%	15,050 $137,000
Q4 2021 Feb 02, 2022	SELL	$13.13 - $24.52 $14,377 - $26,849	-1,095 Reduced 8.33%	12,050 $180,000
Q3 2021 Nov 12, 2021	SELL	$21.01 - $27.64 $36,536 - $48,065	-1,739 Reduced 11.68%	13,145 $338,000
Q2 2021 Aug 03, 2021	SELL	$23.49 - $35.8 $238,165 - $362,976	-10,139 Reduced 40.52%	14,884 $388,000
Q1 2021 May 10, 2021	BUY	$25.79 - $39.02 $645,343 - $976,397	25,023 New	25,023 $883,000
Q2 2020 Aug 11, 2020	SELL	$18.39 - $54.04 $244,587 - $718,732	-13,300 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$18.22 - $28.25 $100,210 - $155,375	5,500 Added 70.51%	13,300 $259,000
Q4 2019 Feb 07, 2020	SELL	$24.82 - $31.4 $270,538 - $342,260	-10,900 Reduced 58.29%	7,800 $203,000
Q3 2019 Oct 31, 2019	BUY	$26.11 - $32.99 $221,935 - $280,415	8,500 Added 83.33%	18,700 $510,000
Q2 2019 Aug 09, 2019	BUY	$25.56 - $31.09 $260,712 - $317,118	10,200 New	10,200 $274,000

Others Institutions Holding ALLO

# of Institutions

162

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Account

Oppenheimer & CO Inc Allogene Therapeutics, Inc. Transaction History